Day One Biopharmaceuticals' (DAWN) Outperform Rating Reiterated at Wedbush

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a note issued to investors on Wednesday, RTT News reports. They currently have a $33.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 114.98% from the stock’s current price. […]

Related Keywords

Samuelc Blackman ,Piper Sandler ,Franklin Resources Inc ,Jpmorgan Chase Co ,Needham Company ,Vanguard Group Inc ,Securities Exchange Commission ,Day One Biopharmaceuticals Inc ,Goldman Sachs Group ,Polar Capital Holdings Plc ,Goldman Sachs Group Inc ,Day One Biopharmaceuticals ,Get Free Report ,One Biopharmaceuticals ,Day One ,Exchange Commission ,Sachs Group ,Capital Holdings Plc ,Day One Biopharmaceuticals Daily ,